Cristina Adriana Dehelean1, Voichita Lazureanu2,3, Dorina Coricovac1, Marius Mioc1, Roxana Oancea4, Iasmina Marcovici1, Iulia Pinzaru1, Codruta Soica1, Aristidis M Tsatsakis5, Octavian Cretu2. 1. Faculty of Pharmacy, "Victor Babes" University of Medicine and Pharmacy, 2nd Eftimie Murgu Sq., 300041 Timisoara, Romania. 2. Faculty of Medicine, "Victor Babes" University of Medicine and Pharmacy, 2nd Eftimie Murgu Sq., 300041 Timisoara, Romania. 3. "Dr. Victor Babes" Clinical Hospital for Infectious Diseases and Pneumophthisiology, 300310 Timisoara, Romania. 4. Faculty of Dental Medicine, "Victor Babes" University of Medicine and Pharmacy, 2nd Eftimie Murgu Sq., 300041 Timisoara, Romania. 5. Department of Forensic Sciences and Toxicology, Faculty of Medicine, University of Crete, Heraklion, 71003 Crete, Greece.
Abstract
SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) pandemic represents the primary public health concern nowadays, and great efforts are made worldwide for efficient management of this crisis. Considerable scientific progress was recorded regarding SARS-CoV-2 infection in terms of genomic structure, diagnostic tools, viral transmission, mechanism of viral infection, symptomatology, clinical impact, and complications, but these data evolve constantly. Up to date, neither an effective vaccine nor SARS-CoV-2 specific antiviral agents have been approved, but significant advances were enlisted in this direction by investigating repurposed approved drugs (ongoing clinical trials) or developing innovative antiviral drugs (preclinical and clinical studies). This review presents a thorough analysis of repurposed drug admitted for compassionate use from a chemical structure-biological activity perspective highlighting the ADME (absorption, distribution, metabolism, and excretion) properties and the toxicophore groups linked to potential adverse effects. A detailed pharmacological description of the novel potential anti-COVID-19 therapeutics was also included. In addition, a comprehensible overview of SARS-CoV-2 infection in terms of general description and structure, mechanism of viral infection, and clinical impact was portrayed.
SARS-CoV-2 (n class="Species">severe acute respiratory syndrome coronavirus 2) pandemic represents the primary public health concern nowadays, and great efforts are made worldwide for efficient management of this crisis. Considerable scientific progress was recorded regarding SARS-CoV-2 infection in terms of genomic structure, diagnostic tools, viral transmission, mechanism of viral infection, symptomatology, clinical impact, and complications, but these data evolve constantly. Up to date, neither an effective vaccine nor SARS-CoV-2 specific antiviral agents have been approved, but significant advances were enlisted in this direction by investigating repurposed approved drugs (ongoing clinical trials) or developing innovative antiviral drugs (preclinical and clinical studies). This review presents a thorough analysis of repurposed drug admitted for compassionate use from a chemical structure-biological activity perspective highlighting the ADME (absorption, distribution, metabolism, and excretion) properties and the toxicophore groups linked to potential adverse effects. A detailed pharmacological description of the novel potential anti-COVID-19 therapeutics was also included. In addition, a comprehensible overview of SARS-CoV-2 infection in terms of general description and structure, mechanism of viral infection, and clinical impact was portrayed.
Authors: Uttpal Anand; Shweta Jakhmola; Omkar Indari; Hem Chandra Jha; Zhe-Sheng Chen; Vijay Tripathi; José M Pérez de la Lastra Journal: Front Immunol Date: 2021-06-30 Impact factor: 7.561
Authors: Ronald N Kostoff; Darja Kanduc; Alan L Porter; Yehuda Shoenfeld; Daniela Calina; Michael B Briggs; Demetrios A Spandidos; Aristidis Tsatsakis Journal: Toxicol Rep Date: 2020-10-22
Authors: Ronald N Kostoff; Michael B Briggs; Alan L Porter; Demetrios A Spandidos; Aristidis Tsatsakis Journal: Int J Mol Med Date: 2020-09-18 Impact factor: 4.101